特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の粒子治療市場:成長、動向、および予測(2020年~2025年)

Particle Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921917
出版日 ページ情報 英文 95 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
世界の粒子治療市場:成長、動向、および予測(2020年~2025年) Particle Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 95 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

世界の粒子治療市場は、予測期間中に8.6%のCAGRで成長する見通しです。同市場の成長を促進している主な要因には、粒子治療によってもたらされる利点や、癌の世界における有病率の増加などが挙げられます。また、粒子線治療のための革新的な技術の研究開発への多額の投資は、予測期間中の市場成長要因として期待されています。

当レポートは世界の粒子治療市場について調査しており、市場機会や動向、成長および阻害要因、タイプ・システム・癌のタイプ・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 粒子線治療が提供する利点
    • 増大する世界的ながんの負担
  • 市場阻害要因
    • 医療施設におけるインフラの課題
    • 不利な償還方針と限定的な保険適用範囲
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • タイプ別
    • プロトン療法
    • 重イオン療法
  • システム別
    • マルチルームシステム
    • シングルルームシステム
  • 癌のタイプ別
    • 小児癌
    • 前立腺癌
    • 肺癌
    • 乳癌
    • 脳および脊髄癌
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他

第6章 競合情勢

  • 企業プロファイル
    • Danfysik A/S
    • 株式会社日立製作所
    • Ion Beam Applications Sa (IBA)
    • Mevion Medical Systems, Inc.
    • Optivus Proton Therapy, Inc.
    • Protom International, Inc.
    • Provision Healthcare, LLC
    • 住友重機械工業株式会社
    • Varian Medical Systems, Inc.

第7章 市場機会および今後の動向

目次
Product Code: 66857

Market Overview

The global Particle Therapy market is expected to witness a CAGR of 8.6% during the forecast period. Certain factors that are driving the market growth include advantages offered by particle therapy and the growing global prevalence of cancer.

The number of people suffering from various cancers has been found to be a major driving factor for this market. Cancer is one of the major life-threatening diseases of our times. According to the WHO, cancer is the second leading cause of death, globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about one in six deaths are due to cancer. Approximately 70% of deaths from cancer occur in low and middle-income countries. According to the American Cancer Society, nearly 40,000 people in the United States were diagnosed with head and neck cancer, of which, 12,000 died in the year 2014 alone. Head and neck cancer account for nearly 5-6% of the cancer cases in the United States. It is the 15th most prevalent type of cancer in Europe, with nearly 56,000 cases diagnosed annually. Since particle therapies are used to treat cancer, the growing prevalence of the same is expected to be the major driver of the growth of this market.

Scope of the Report

Particle therapy is a cutting-edge area of external beam radiotherapy. It uses beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment.

Key Market Trends

Particle Therapy in Prostate Cancer is Expected to Hold a Significant Share Over the Forecast Period

Prostate cancer is the second most common type of cancer affecting the male reproductive system. About 80% of men who reach 80 years of age are diagnosed with it. As per the estimates provided by the American Cancer Society, in 2018, the United States witnessed over 164,690 new cases of prostate cancer, with over 29,430 related deaths. About 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime. Thus, considering the aforementioned factors, the concerned segment of the market is expected to witness high growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America dominated the global market studied, in 2018. Almost half of all cancer patients in the region, especially in the United States receive cancer treatment. The United States has the largest market for radiotherapy. The market is driven by factors, such as increasing incidences of cancer, replacements of older therapies with newer ones, and the availability of reimbursements for radiation therapy. A few states in the United States have passed laws compelling the personnel performing radiologic procedures to hold licenses. The changes in legislature and availability of reimbursement policies have led to incentivizing the providers to improve patient care and outcomes of treatment while controlling the costs. With large investments being made in R&D of innovative technologies for particle therapy, the market is expected to grow during the forecast period.

Competitive Landscape

The global Particle Therapy market is highly competitive and consists of a number of major players. Companies like Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc., among others, hold the substantial market share in the Particle Therapy market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Advantages Offered By Particle Therapy
    • 4.2.2 Growing Global Burden of Cancer
  • 4.3 Market Restraints
    • 4.3.1 Infrastructural Challenges in Healthcare Facilities
    • 4.3.2 Unfavorable Reimbursement Policies and Limited Insurance Coverage
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Proton Therapy
    • 5.1.2 Heavy Ion Therapy
  • 5.2 By System
    • 5.2.1 Multi-Room Systems
    • 5.2.2 Single-Room Systems
  • 5.3 By Cancer Type
    • 5.3.1 Pediatric Cancer
    • 5.3.2 Prostate Cancer
    • 5.3.3 Lung Cancer
    • 5.3.4 Breast Cancer
    • 5.3.5 Brain and Spinal Cord Cancer
    • 5.3.6 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Danfysik A/S
    • 6.1.2 Hitachi, Ltd.
    • 6.1.3 Ion Beam Applications Sa (IBA)
    • 6.1.4 Mevion Medical Systems, Inc.
    • 6.1.5 Optivus Proton Therapy, Inc.
    • 6.1.6 Protom International, Inc.
    • 6.1.7 Provision Healthcare, LLC
    • 6.1.8 Sumitomo Heavy Industries, Ltd.
    • 6.1.9 Varian Medical Systems, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS